Interferon-?2b induction treatment with or without ribavirin in chronic hepatitis C: A multicenter, randomized, controlled trial

Basit Öğe Kaydı
dc.contributor.authorSenturk H.
dc.contributor.authorErsoz G.
dc.contributor.authorOzaras R.
dc.contributor.authorKaymakoglu S.
dc.contributor.authorBozkaya H.
dc.contributor.authorAkdogan M.
dc.contributor.authorMert A.
dc.contributor.authorBozdayi M.
dc.contributor.authorTabak F.
dc.contributor.authorYenice N.
dc.contributor.authorOzbay G.
dc.date.accessioned2019-10-27T08:59:42Z
dc.date.available2019-10-27T08:59:42Z
dc.date.issued2003
dc.departmentEge Üniversitesien_US
dc.description.abstractWe aimed to compare the efficacy of interferon-?2b (IFN) induction treatment in combination with ribavirin to IFN induction alone in chronic hepatitis C. In total, 125 patients (66 male, 59 female, mean age: 48 ± 9, range: 21-70) were enrolled and randomized into two arms: In the first, patients received 5 MU/day of IFN for 4 weeks followed by 3 MU/day for the next 4 weeks. Treatment was continued with 3 MU three times a week IFN for an additional 40 weeks. Ribavirin was administered 1000-1200 mg/day according to the body weight for the entire 48-week period. In the second arm, patients received placebo in addition to IFN. Fifty-nine patients were placed in the ribavirin arm and 66 in placebo arm. All patients were genotype 1. At week 48, 24/66 (36%) from the placebo and 31/59 (52%) from the ribavirin group responded (P > 0.05). However, during the 24-week untreated follow-up period, 13/24 (54%) from the placebo, and 8/31 (26%) from the ribavirin group relapsed (P = 0.002.), resulting in a sustained virologic response (SVR) rate of 17% in the placebo and 39% in the ribavirin group (P = 0.005.) In conclusion, IFN induction treatment in combination with ribavirin is superior to IFN induction treatment alone in genotype 1 patients, and the SVR rate of 39% is encouraging.en_US
dc.identifier.doi10.1023/A:1023725014751en_US
dc.identifier.endpage1129en_US
dc.identifier.issn0163-2116
dc.identifier.issue6en_US
dc.identifier.pmid12822874en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1124en_US
dc.identifier.urihttps://doi.org/10.1023/A:1023725014751
dc.identifier.urihttps://hdl.handle.net/11454/27882
dc.identifier.volume48en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofDigestive Diseases and Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic hepatitis Cen_US
dc.subjectCombination drugen_US
dc.subjectInterferon ?en_US
dc.subjectRibavirinen_US
dc.subjectTherapyen_US
dc.titleInterferon-?2b induction treatment with or without ribavirin in chronic hepatitis C: A multicenter, randomized, controlled trialen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu